drug
teclistamab
Marketedupdated 3mo agoby Janssen Biotech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(11)
approval · 11
Oct 25, 2022
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Aug 9, 2023
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Nov 16, 2023
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Feb 20, 2024
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
May 28, 2024
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Jul 2, 2024
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Nov 22, 2024
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Dec 2, 2024
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Aug 19, 2025
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Oct 2, 2025
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Mar 5, 2026
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Trials studying teclistamab
- phase1A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- phase2A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- phase3A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- phase3A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- phase3A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- phase1A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- phase2A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- phase2A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
News(6)
- Legend Biotech CEO abruptly steps down without permanent replacementIn a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.fiercebiotech · 19d ago
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.biopharma_dive · 21d ago
- ‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D winsA string of recent wins on the frontiers of novel drug development could mean that a homegrown innovation industry is within reach.fiercebiotech · 29d ago
- On second try, Acadia drug gets nod from European regulatorsThe influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.biopharma_dive · 1mo ago
- CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineA Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.biopharma_dive · 3mo ago
- FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotechThrough two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…biopharma_dive · 3mo ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that